New Roche breast cancer treatment approved in US
The FDA approved Roche's Wilserdly (giredestrant) with everolimus for ER-positive, HER2-negative, ESR1-mutated breast cancer. Roche expects sales from 2027, with estimates ranging from $500M to $600M annually. The treatment costs $22,500/month and aims to delay disease progression. Roche's Chief Medical Officer highlights its benefits for advanced breast cancer patients.
How this was made

The 30-second read
Why it matters
This is a regulatory de-risking event that can accelerate commercialization planning and investor expectations for Roche’s oncology growth, while also highlighting pricing pressure and payer dynamics.
Market read
Traders can reassess Roche’s oncology revenue outlook and competitive positioning following a US FDA approval with stated launch timing and consensus revenue expectations.
What to watch
Real-world uptake will depend on payer coverage, sequencing versus existing endocrine therapies, and safety/tolerability in broader practice beyond the trial population.
Background
The FDA approval covers Wilserdly (giredestrant) in combination with everolimus for locally advanced or metastatic ER-positive, HER2-negative breast cancer with an ESR1 mutation, including patients whose disease recurred or progressed on endocrine therapy.
Ticker impact
Roche’s US subsidiary Genentech received FDA approval for Wilserdly (giredestrant) plus everolimus in ER-positive, HER2-negative, ESR1-mutated advanced breast cancer.
Likely positive bias as investors price in incremental sales ramp and competitive positioning in ESR1-mutant breast cancer.
The article is a direct FDA approval with explicit commercialization expectations (launch contribution from next year, first full year 2027) and quantified market-consensus revenue range.
Market effects
Reinforces competitive intensity in endocrine-resistant, ESR1-mutant breast cancer and may shift relative expectations versus other oral SERD programs.
Supports sentiment toward European pharma/oncology names with US regulatory catalysts.
US label expansion can influence global pricing and uptake expectations for similar targeted endocrine therapies.
Counterpoint
Peak-sales and consensus revenue figures are uncertain, and list-price does not guarantee net pricing or payer acceptance.
Key entities
- companyRoche
Swiss pharma group; FDA approval for Wilserdly plus everolimus via its US subsidiary Genentech.
- companyGenentech
Roche’s US subsidiary referenced as the developer of the therapy for the FDA approval.
- drugWilserdly (giredestrant)
Oral targeted therapy approved with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer.
- drugeverolimus
Partner therapy used in combination with Wilserdly in the approved regimen.
- regulatorFDA
US regulator that approved the combination therapy and included prescribing information warnings.


